Input-Output models

Simulation for Designing Clinical Trials: A Pharmacokinetic-Pharmacodynamic Modeling Perspective

Volumn , Issue , 2002, Pages 17-30

  Holford, Nicholas H G ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84968857424     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (8)

1. NHG Holford, M Hale, HC Ko, J-L Steimer, LB Sheiner, CC Peck. Simulation in drug development: good practices, 1999. http://cdds.georgetown.edu/sddgp723.html
2. GEP Box. Robustness in the strategy of scientific model building. In: RL Launer, GN Wilkinson, eds. Robustness in Statistics. New York: Academic Press, 1979, p 202.
3. NHG Holford. A size standard for pharmacokinetics. Clin Pharmacokinet 30:329-332, 1996.
4. MO Karlsson, LB Sheiner. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 21(6):735-750, 1993.
5. NHG Holford. Target concentration intervention: beyond Y2K. British J Clin Pharmacol 48:9-13, 1999.
6. NHG Holford. Concentration controlled therapy. In: A Breckenridge, ed. Esteve Foundation Workshop. Amsterdam: Elsevier Science, 2001.
7. GB West, JH Brown, BJ Enquist. A general model for the origin of allometric scaling laws in biology. Science 276:122-126, 1997.
8. GB West, JH Brown, BJ Enquist. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 284(5420):1677-1679, 1999.